Biologic therapy targeting IL-17 = Biologic therapy targeting IL-17

다국어 초록 (Multilingual Abstract)

Psoriasis is a common immune-mediated inflammatory skin disease with dominant epidermal hyperplasia caused by the excessive secretion of inflammatory cytokines. Current advances in immunologic research have enhanced our understanding of the pathogenesis and treatment of psoriasis. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 inhibitor. Further discovery of antibodies targeting IL-17A (ixekizumab and secukinumab) and the IL-17 receptor subunit (brodalumab) have shown higher levels of efficacy in a greater portion of patients. By this presentation, I would like to provide a brief review on the immune abnormalities and the role of IL-17 in psoriasis, and to discuss recent data on the efficacy and safety profile of IL-17 inhibitors, especially focusing on secukinumab with emphasis on practical daily use.